Long term survival in a patient with variant Creutzfeldt-Jakob disease treated with intraventricular pentosan polysulphate.
Variant Creutzfeldt-Jakob disease (vCJD) is a neurodegenerative disease that principally affects young people and has a median duration of illness of 13 (range 6-39) months. vCJD is incurable and there are currently no treatments that conclusively slow the rate of disease progression. However, recent animal studies and isolated case reports have suggested that treatment with intraventricular pentosan polysulphate (PPS) may be beneficial in the treatment of patients with vCJD. We report a case of a 22-year-old male with vCJD treated 19 months after the onset of clinical symptoms with continuous intraventricular PPS (32 microg/kg/day) over a period of 31 months. Treatment with PPS appeared to be safe and well tolerated and was associated with prolonged survival (51 months) when compared to natural history studies. However, PPS treatment did not appear to arrest the progression of the disease.
Parry
A
A
Department of Neurology, John Radcliffe Hospital, Headley Way, Headington, Oxford OX3 9DU, UK. allysonparry@hotmail.com
Baker
I
I
Stacey
R
R
Wimalaratna
S
S
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage*; D007562:Creutzfeldt-Jakob Syndrome / Q000188:drug therapy*; D018450:Disease Progression; D006801:Humans; D007276:Injections, Intraventricular; D008297:Male; D010426:Pentosan Sulfuric Polyester / Q000008:administration & dosage*; D016019:Survival Analysis; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010426:Pentosan Sulfuric Polyester